دورية أكاديمية
أعرض في EDS

An Open-label Pilot Study of NicoBloc as a Novel Smoking Cessation Intervention.

التفاصيل البيبلوغرافية
العنوان: An Open-label Pilot Study of NicoBloc as a Novel Smoking Cessation Intervention.
المؤلفون: Chichester KR; From the Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL (KRC, MLS, SMC, CW-C, MJH, ESH, PP, AN, KLC); Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC (JD); Hollings Cancer Center, Medical University of South Carolina, Charleston, SC (JD); and School of Public Health, University of Alabama at Birmingham, Birmingham, AL (PSH)., Sisson ML, Chana SM, Wolford-Clevenger C, Hugley MJ, Hawes ES, Palenski P, Nguyen A, Dahne J, Hendricks PS, Cropsey KL
المصدر: Journal of addiction medicine [J Addict Med] 2023 Jul-Aug 01; Vol. 17 (4), pp. e269-e277. Date of Electronic Publication: 2023 Mar 03.
نوع المنشور: Randomized Controlled Trial; Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: Netherlands NLM ID: 101306759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-3227 (Electronic) Linking ISSN: 19320620 NLM ISO Abbreviation: J Addict Med Subsets: MEDLINE
أسماء مطبوعة: Publication: [Alphen aan den Rijn, the Netherlands] : Wolters Kluwer Health, Inc.
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Nicotine* , Smoking Cessation*/methods, Humans ; Pilot Projects ; Tobacco Use Cessation Devices ; Tablets
مستخلص: Introduction: NicoBloc is a viscous fluid applied to the cigarette filter designed to block tar and nicotine. This novel and understudied smoking cessation device presents a nonpharmacological means for smokers to gradually reduce nicotine and tar content while continuing to smoke their preferred brand of cigarette. This pilot study aimed to assess the feasibility, acceptability, and initial efficacy of NicoBloc as compared with nicotine replacement therapy (nicotine lozenge).
Methods: A community sample of predominately Black smokers (N = 45; 66.7% Black) were randomized to receive NicoBloc or nicotine lozenge. Both groups engaged in 4 weeks of smoking cessation therapy followed by 2 months of independent usage with monthly check-ins to assess medication adherence. The intervention lasted 12 weeks, and the study concluded with a 1-month postintervention follow-up visit (week 16).
Results: NicoBloc was comparable with nicotine lozenge in smoking reduction, feasibility, symptom adverse effects, and reported acceptability at week 16. Participants in the lozenge group endorsed higher treatment satisfaction ratings during the intervention and lower cigarette dependence. Adherence to NicoBloc was superior throughout the study.
Conclusion: NicoBloc was feasible and acceptable to community smokers. NicoBloc presents a unique, nonpharmacological intervention. Future research is needed to examine whether this intervention may be most effective in subpopulations where pharmacological approaches are restricted or in combination with established pharmacological methods such as nicotine replacement therapy.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2023 American Society of Addiction Medicine.)
References: Nicotine Tob Res. 2012 Jan;14(1):75-8. (PMID: 22025545)
Nicotine Tob Res. 2008 Aug;10(8):1405-13. (PMID: 18686189)
Arch Gen Psychiatry. 1986 Mar;43(3):289-94. (PMID: 3954551)
Nicotine Tob Res. 2009 Mar;11(3):234-9. (PMID: 19246427)
Addict Behav. 2017 Apr;67:92-99. (PMID: 28063325)
Pharmacol Biochem Behav. 1998 Aug;60(4):817-21. (PMID: 9700963)
Nicotine Tob Res. 2015 Nov;17(11):1385-92. (PMID: 25646352)
Nicotine Tob Res. 2015 Aug;17(8):968-74. (PMID: 26180221)
Clin Trials. 2012 Dec;9(6):767-76. (PMID: 23169874)
Nicotine Tob Res. 2020 Aug 24;22(9):1533-1542. (PMID: 31667501)
Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):159-65. (PMID: 9164567)
Urology. 2012 Jul;80(1):104-9. (PMID: 22748869)
Addiction. 2010 Feb;105(2):343-55. (PMID: 20078491)
Nicotine Tob Res. 2008 Jul;10(7):1139-48. (PMID: 18629723)
Trials. 2020 Sep 11;21(1):784. (PMID: 32917258)
J Subst Abuse Treat. 2004 Jul;27(1):17-25. (PMID: 15223089)
Br J Addict. 1991 Nov;86(11):1467-76. (PMID: 1777741)
Cochrane Database Syst Rev. 2018 May 31;5:CD000146. (PMID: 29852054)
Behav Pharmacol. 2001 Jul;12(4):277-84. (PMID: 11548113)
Clin Ther. 2008 Oct;30(10):1852-8. (PMID: 19014840)
Tob Control. 2015 Nov;24(6):536-9. (PMID: 25192771)
Drug Alcohol Depend. 2009 Sep 1;104(1-2):23-33. (PMID: 19446968)
Nicotine Tob Res. 2013 May;15(5):978-82. (PMID: 22990219)
JAMA Intern Med. 2019 Feb 1;179(2):167-174. (PMID: 30556832)
Nepal J Epidemiol. 2020 Sep 30;10(3):878-887. (PMID: 33042591)
CNS Drugs. 2001;15(6):453-67. (PMID: 11524024)
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2479-85. (PMID: 18006940)
J Consult Clin Psychol. 2004 Apr;72(2):139-54. (PMID: 15065950)
Tob Induc Dis. 2010 Jul 13;8:8. (PMID: 20626883)
Addiction. 2020 Feb;115(2):201-217. (PMID: 31454123)
J Addict Med. 2019 Jul/Aug;13(4):322-330. (PMID: 30664539)
Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286. (PMID: 27009521)
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097. (PMID: 31570931)
معلومات مُعتمدة: K23 DA045766 United States DA NIDA NIH HHS; R01 DA039678 United States DA NIDA NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT03720899
المشرفين على المادة: 6M3C89ZY6R (Nicotine)
0 (Tablets)
تواريخ الأحداث: Date Created: 20230814 Date Completed: 20231102 Latest Revision: 20240304
رمز التحديث: 20240304
مُعرف محوري في PubMed: PMC10480353
DOI: 10.1097/ADM.0000000000001157
PMID: 37579108
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-3227
DOI:10.1097/ADM.0000000000001157